Net product sales in SCD market: Oxbryta & Adakveo

DONATE


Last Update: Aug 8, 2022

in millions, $, exc. Rx Q419 Q120 Q220 Q320 Q420 Q121 Q221 Q321 Q421 Q122 Q222 FY 2019 2020 2021
Oxbryta New Oxbryta Prescriptions 350 1,650 1,000 1,000 950 950 925 850 800 1,200 ** 350 4,600 3,525
Total Oxbryta Prescriptions 350 1,650 2,650 3,100 4,050 5,000 5,925 6,775 7,575 8,775 ** 350 11,450 25,275
Global Oxbryta Revenue 2 14 32 37 41 39 48 52 56 55 72 2 124 195
Adakveo Global Adakveo Revenue - 15 21 35 34 37 42 42 43 44 49 - 105 164
SCD prevalence - US 95,000 95,000 95,000 95,000 95,000 95,000 95,000 95,000 95,000 95,000 95,000 95,000 95,000 95,000
SCD prevalence - EU 60,000 60,000 60,000 60,000 60,000 60,000 60,000 60,000 60,000 60,000 60,000 60,000 60,000 60,000
Net product sales of Oxbryta & Adakveo by quarter and year. Oxbryta U.S. list price: $125,000/yr (WAC). Adakveo U.S list price: $85,000-115,000/yr (WAC). Notes: Oxbryta and Adakveo labels do not overlap completely. SCD prevalence numbers are approximations. Oxbryta was launched in Germany mid-May. Adakveo received NICE recommendation (UK) in October 2021. ** Unreleased - Pfizer agreed to acquire GBT prior to earnings release.

SUBSCRIBE